Elevation Oncology (ELEV) Short Interest Ratio & Short Volume → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free ELEV Stock Alerts $3.61 -0.12 (-3.22%) (As of 04:27 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Elevation Oncology Short Interest DataCurrent Short Volume4,890,000 sharesPrevious Short Volume4,950,000 sharesChange Vs. Previous Month-1.21%Dollar Volume Sold Short$17.36 millionShort Interest Ratio / Days to Cover4.9Last Record DateApril 30, 2024Outstanding Shares54,640,000 sharesFloat Size42,660,000 sharesShort Percent of Float11.46%Today's Trading Volume272,182 sharesAverage Trading Volume2,310,387 sharesToday's Volume Vs. Average12% Short Selling Elevation Oncology ? Sign up to receive the latest short interest report for Elevation Oncology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatELEV Short Interest Over TimeELEV Days to Cover Over TimeELEV Percentage of Float Shorted Over Time Ad Unstoppable ProsperityCharles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. Elevation Oncology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20244,890,000 shares $17.36 million -1.2%11.5%4.9 $3.55 4/15/20244,950,000 shares $21.93 million -1.2%13.0%4.2 $4.43 3/31/20245,010,000 shares $25.70 million +8.2%12.6%1.6 $5.13 3/15/20244,630,000 shares $20.33 million +28.3%11.6%1.6 $4.39 2/29/20243,610,000 shares $15.92 million -10.0%9.1%1.3 $4.41 2/15/20244,010,000 shares $11.11 million +13.9%11.6%1.5 $2.77 Get the Latest News and Ratings for ELEV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. 1/31/20243,520,000 shares $9.79 million +95.6%10.1%1.4 $2.78 1/15/20241,800,000 shares $4.93 million +124.0%5.2%0.8 $2.74 12/31/2023803,700 shares $431,586.90 +21.0%2.5%0.5 $0.54 12/15/2023664,500 shares $338,961.45 +12.0%2.1%2.8 $0.51 11/30/2023593,500 shares $315,742.00 -10.8%1.8%2.7 $0.53 11/15/2023665,100 shares $307,276.20 -22.3%2.1%2.9 $0.46 10/31/2023856,100 shares $410,928.00 -8.2%2.8%4.1 $0.48 10/15/2023932,200 shares $616,184.20 +0.6%3.1%5.6 $0.66 9/30/2023926,500 shares $613,898.90 -24.7%3.1%4.9 $0.66 9/15/20231,230,000 shares $895,440.00 +1.7%4.1%5.5 $0.73 8/31/20231,210,000 shares $924,440.00 -4.7%5.2%2.6 $0.76 8/15/20231,270,000 shares $1.16 million +0.8%5.4%0.8 $0.91 7/31/20231,260,000 shares $1.51 million -4.6%4.7%0.7 $1.20 7/15/20231,320,000 shares $1.97 million -11.4%8.6%0.7 $1.49 6/30/20231,490,000 shares $2.26 million -4.5%9.8%0.8 $1.52 6/15/20231,560,000 shares $2.31 million -39.3%10.2%0.8 $1.48 5/31/20232,570,000 shares $10.85 million +596.3%16.4%1.2 $4.22 5/15/2023369,100 shares $1.35 million -64.2%2.3%0.4 $3.67 4/30/20231,030,000 shares $2.71 million +688.7%6.7%1.3 $2.63 4/15/2023130,600 shares $254,670.00 +6.0%0.9%0.3 $1.95 3/31/2023123,200 shares $234,080.00 +135.6%0.8%0.2 $1.90 3/15/202352,300 shares $121,336.00 +28.2%0.3%0.1 $2.32 2/28/202340,800 shares $44,982.00 +22.5%0.3%0.4 $1.10 2/15/202333,300 shares $32,634.00 -18.2%0.2%0.4 $0.98 1/31/202340,700 shares $40,700.00 +20.8%0.3%0.5 $1.00 1/15/202333,700 shares $33,396.70 -29.4%0.2%0.4 $0.99 12/30/202247,700 shares $45,315.00 +10.7%0.3%0.7 $0.95 12/15/202243,100 shares $40,945.00 -2.1%0.3%1.1 $0.95 11/30/202244,000 shares $39,776.00 -10.4%0.3%1 $0.90 11/15/202249,100 shares $47,627.00 +6.1%0.3%1 $0.97 10/31/202246,300 shares $50,004.00 +42.5%0.3%0.9 $1.08 10/15/202232,500 shares $35,425.00 -62.7%0.2%0.5 $1.09 9/30/202287,200 shares $98,536.00 +76.5%0.6%1.1 $1.13 9/15/202249,400 shares $61,750.00 -12.6%0.3%0.5 $1.25The most important AI company you've never heard of (Ad)Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.Get the full story on this secret AI company poised for massive growth ELEV Short Interest - Frequently Asked Questions What is Elevation Oncology's current short interest? Short interest is the volume of Elevation Oncology shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 4,890,000 shares of ELEV short. 11.46% of Elevation Oncology's shares are currently sold short. Learn More on Elevation Oncology's current short interest. What is a good short interest ratio for Elevation Oncology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ELEV shares currently have a short interest ratio of 5.0. Learn More on Elevation Oncology's short interest ratio. What is a good short interest percentage for Elevation Oncology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.46% of Elevation Oncology's floating shares are currently sold short. Is Elevation Oncology's short interest increasing or decreasing? Elevation Oncology saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 4,890,000 shares, a drop of 1.2% from the previous total of 4,950,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Elevation Oncology's float size? Elevation Oncology currently has issued a total of 54,640,000 shares. Some of Elevation Oncology's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Elevation Oncology currently has a public float of 42,660,000 shares. How does Elevation Oncology's short interest compare to its competitors? 11.46% of Elevation Oncology's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Elevation Oncology: Fennec Pharmaceuticals Inc (7.82%), Kodiak Sciences Inc. (3.76%), Adverum Biotechnologies, Inc. (8.04%), Century Therapeutics, Inc. (5.00%), Genfit S.A. (0.18%), INmune Bio, Inc. (13.54%), Compugen Ltd. (2.25%), Opthea Limited (0.22%), Innate Pharma S.A. (0.10%), Cellectis S.A. (1.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Elevation Oncology stock? Short selling ELEV is an investing strategy that aims to generate trading profit from Elevation Oncology as its price is falling. ELEV shares are trading up $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Elevation Oncology? A short squeeze for Elevation Oncology occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ELEV, which in turn drives the price of the stock up even further. How often is Elevation Oncology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ELEV, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: FENC Short Interest Data KOD Short Interest Data ADVM Short Interest Data IPSC Short Interest Data GNFT Short Interest Data INMB Short Interest Data CGEN Short Interest Data OPT Short Interest Data IPHA Short Interest Data CLLS Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ELEV) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research